Dissolution of an Employees' Pension Fund and Costs of Revising the Retirement Benefit Plan
First written in FY2017. 2 of 5 entries say "Materialised", first in FY2018-Q1. Latest entry: FY2018.
1 other company's latest entry also says "Restated".
- FY2018RestatedAnnual report
「Following the fund's receipt of approval for dissolution from the Minister of Health, Labour and Welfare on 28 March 2018, we transferred funds to the defined contribution pension plan and contributed the shortfall between the expected distribution from the fund after its dissolution and the amount required. Accordingly, the amount was recorded as an extraordinary loss in the current consolidated fiscal year.」
Reconfirms approval for the dissolution of the Osaka Pharmaceutical Industry Employees' Pension Fund, transfers and contributions to the defined contribution pension plan, and the recognition of a ¥261.386 million loss on the revision of the retirement benefit plan. - FY2018-Q3RestatedAnnual report
「The Osaka Pharmaceutical Industry Employees' Pension Fund, in which the company and certain consolidated subsidiaries had participated, was approved for dissolution on 28 March 2018. To maintain employee benefits, the company and certain consolidated subsidiaries had resolved at a Board of Directors meeting held on 20 October 2017 to cover the shortfall between the estimated fund distribution after dissolution and the amount required. Based on this resolution, they made contributions to a defined contribution plan when the fund was dissolved. Accordingly, an extraordinary loss was recognized in the second quarter of the fiscal year ending November 2018.」
Reconfirms approval for the dissolution of the Osaka Pharmaceutical Industry Employees' Pension Fund, contributions to the defined contribution plan upon dissolution, and the recognition in the second quarter of a ¥261.386 million loss on the revision of the retirement benefit plan. - FY2018-Q2MaterialisedAnnual report
「The Osaka Pharmaceutical Industry Employees' Pension Fund, in which the company and certain consolidated subsidiaries had participated, was approved for dissolution on 28 March 2018. To maintain employee benefits, the company and certain consolidated subsidiaries had resolved at a Board of Directors meeting held on 20 October 2017 to cover the shortfall between the estimated fund distribution after dissolution and the amount required. Based on this resolution, they made contributions to a defined contribution plan when the fund was dissolved. Accordingly, the company recognized a ¥261.386 million extraordinary loss in the second quarter of the fiscal year ending November 2018.」
The application to dissolve the Employees' Pension Fund was approved, contributions to a defined contribution plan were made upon dissolution, and a ¥261 million loss on revision of the retirement benefit plan was recognized. - FY2018-Q1MaterialisedAnnual report
「The Osaka Pharmaceutical Industry Employees' Pension Fund, in which the company and certain consolidated subsidiaries had participated, was approved for dissolution on 28 March 2018. To maintain employee benefits, the company and certain consolidated subsidiaries had resolved at a Board of Directors meeting held on 20 October 2017 to cover the shortfall between the estimated fund distribution after dissolution and the amount required. Based on this resolution, they made contributions to a defined contribution plan when the fund was dissolved. Accordingly, the company planned to recognize a ¥265 million extraordinary loss in the second quarter of the fiscal year ending November 2018.」
The planned dissolution of the Osaka Pharmaceutical Industry Employees' Pension Fund was approved, and contributions to a defined contribution plan were made when the fund was dissolved. The associated ¥265 million extraordinary loss was scheduled to be recognized in the second quarter. - FY2017First statedAnnual report
「The Osaka Pharmaceutical Industry Employees' Pension Fund, in which the company and certain consolidated subsidiaries participated, resolved to dissolve the fund and take related measures at a meeting of its representatives held on 5 July 2016. According to the fund, an application for dissolution was scheduled to be filed on 28 March 2018. At a Board of Directors meeting held on 20 October 2017, the company and certain consolidated subsidiaries resolved to maintain employee benefits by covering the shortfall between the estimated fund distribution after dissolution and the amount required, using funds from the company and certain consolidated subsidiaries. Accordingly, the company planned to recognize a ¥265 million extraordinary loss in the second quarter of the fiscal year ending November 2018 to revise the retirement benefit plans of the company and one consolidated subsidiary.」
The company stated that an application to dissolve the Osaka Pharmaceutical Industry Employees' Pension Fund was scheduled to be filed, that it would cover the shortfall, and that it planned to recognize a ¥265 million extraordinary loss in the second quarter of the fiscal year ending November 2018.